Literature DB >> 9135407

Coronal approach for rehabilitative orbital decompression in Graves' ophthalmopathy.

R Kalmann1, M P Mourits, J P van der Pol, L Koornneef.   

Abstract

AIMS: To determine the effectiveness and safety of three wall orbital decompression by the coronal approach in Graves' ophthalmopathy.
METHODS: The records of 125 patients with Graves' ophthalmopathy, who had undergone three wall orbital decompression by coronal approach between April 1984 and October 1993, were studied retrospectively. Special attention was paid to proptosis reduction, changes in ocular motility, and complications.
RESULTS: The preoperative Hertel values ranged from 15 to 30 mm (mean 22.43 mm). The mean proptosis reduction was 4.34 mm (range 0-10 mm). Proptosis reduction in patients with preoperative Hertel values higher than 27 mm was significantly more than in patients with preoperative values between 25 and 27 mm (p < 0.05). This last group showed significantly more proptosis reduction than patients with preoperative Hertel values of 23 and 24 mm (p < 0.01). Postoperatively, 3.2% of the patients showed new diplopia in primary and/or reading position. In 4% of the patients with normal ocular motility preoperatively, diplopia in the extreme directions of gaze developed. In 4% of the patients, preoperative motility disturbances decreased or disappeared postoperatively.
CONCLUSION: Three wall orbital decompression by coronal approach is a safe and effective technique, to achieve proptosis reduction in patients with Graves' ophthalmopathy, with fewer complications than other techniques thus far described.

Entities:  

Mesh:

Year:  1997        PMID: 9135407      PMCID: PMC1722000          DOI: 10.1136/bjo.81.1.41

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  19 in total

1.  Transantral orbital decompression for malignant exophthalmos.

Authors:  T E WALSH; J H OGURA
Journal:  Laryngoscope       Date:  1957-06       Impact factor: 3.325

2.  Surgical correction of exophthalmos secondary to Graves' disease.

Authors:  S R Thaller; H K Kawamoto
Journal:  Plast Reconstr Surg       Date:  1990-09       Impact factor: 4.730

3.  [Basedowian orbitopathy].

Authors:  D Krastinova; A Rodallec
Journal:  Ann Chir Plast Esthet       Date:  1985       Impact factor: 0.660

4.  Orbital decompression for Graves' ophthalmopathy by inferomedial, by inferomedial plus lateral, and by coronal approach.

Authors:  M P Mourits; L Koornneef; W M Wiersinga; M F Prummel; A Berghout; R van der Gaag
Journal:  Ophthalmology       Date:  1990-05       Impact factor: 12.079

5.  Long-term follow-up and recent observations on 305 cases of orbital decompression for dysthyroid orbitopathy.

Authors:  J D Warren; J G Spector; R Burde
Journal:  Laryngoscope       Date:  1989-01       Impact factor: 3.325

6.  [Surgical widening of the orbit. Orbits too small. Basedow exophtalmos. Exorbitisms of cranio-facial dysostosis. Congenital anophthalmia, mivrophalmia. Orbital atresia of young enucleasted eyes. Orbital tumors (angioma, meningioma, Recklinghausen)].

Authors:  P Tessier
Journal:  Ann Chir Plast       Date:  1969

7.  Orbital decompression for severe dysthyroid eye disease.

Authors:  P Fells
Journal:  Br J Ophthalmol       Date:  1987-02       Impact factor: 4.638

8.  Orbital decompression for Graves' disease. Exposure through lateral canthal and inferior fornix incision.

Authors:  C D McCord
Journal:  Ophthalmology       Date:  1981-06       Impact factor: 12.079

9.  An individualized approach to orbital decompression in Graves' orbitopathy.

Authors:  J J Hurwitz; D Birt
Journal:  Arch Ophthalmol       Date:  1985-05

10.  Current trends in orbital decompression.

Authors:  C D McCord
Journal:  Ophthalmology       Date:  1985-01       Impact factor: 12.079

View more
  10 in total

Review 1.  [Endocrine orbit disorders. Pathogenesis, clinical presentation and examination, stage-dependent therapy].

Authors:  A Eckstein; J Esser
Journal:  Ophthalmologe       Date:  2003-10       Impact factor: 1.059

2.  Thyroid-associated orbitopathy.

Authors:  Adel H Alsuhaibani; Jeffrey A Nerad
Journal:  Semin Plast Surg       Date:  2007-02       Impact factor: 2.314

Review 3.  Pharmacological treatments for thyroid eye disease.

Authors:  Sara P Modjtahedi; Bobeck S Modjtahedi; Ahmad M Mansury; Dinesh Selva; Raymond S Douglas; Robert A Goldberg; Igal Leibovitch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 4.  Iatrogenic diplopia [corrected].

Authors:  Julio González-Martín-Moro; Julio José González-López; Marco Sales-Sanz; Andrea Sales-Sanz; Javier González-Martín-Moro; Fernando Gómez-Sanz; Mar González-Manrique; Belén Pilo-de-la-Fuente; Roberto García-Leal
Journal:  Int Ophthalmol       Date:  2014-03-07       Impact factor: 2.031

5.  Thyroid-Related Orbital Decompression Surgery: A Multivariate Analysis of Risk Factors and Outcomes.

Authors:  Chris Y Wu; Leslie M Niziol; David C Musch; Alon Kahana
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2017 May/Jun       Impact factor: 1.746

Review 6.  [Endocrine orbitopathy 1998].

Authors:  G Förster; G Kahaly
Journal:  Med Klin (Munich)       Date:  1998-06-15

7.  [Lateral orbital decompression for Graves' orbitopathy. Indication, surgical technique, and treatment success].

Authors:  N Fichter; M P Schittkowski; H P Vick; R F Guthoff
Journal:  Ophthalmologe       Date:  2004-04       Impact factor: 1.059

8.  Graded decompression of orbital fat and wall in patients with Graves' orbitopathy.

Authors:  Kyou Ho Lee; Sun Young Jang; Sang Yeul Lee; Jin Sook Yoon
Journal:  Korean J Ophthalmol       Date:  2014-01-21

Review 9.  Surgical complications in orbital decompression for Graves' orbitopathy.

Authors:  S Sellari-Franceschini; I Dallan; A Bajraktari; G Fiacchini; M Nardi; R Rocchi; C Marcocci; M Marinò; A P Casani
Journal:  Acta Otorhinolaryngol Ital       Date:  2016-08       Impact factor: 2.124

Review 10.  Orbital decompression in thyroid eye disease.

Authors:  N Fichter; R F Guthoff; M P Schittkowski
Journal:  ISRN Ophthalmol       Date:  2012-11-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.